Iambic Therapeutics, Inc.
San Diego, US · Founded 2019 · Delaware corporation · 3 known investors
Founders & leadership
Iambic Therapeutics, Inc. was founded in 2019 by Fred Manby and Thomas Miller.
FM
Fred ManbyCo-founder
TM
Thomas MillerCo-founder
NJ
Neil JosephsonExecutive
MS
Michael SecoraExecutive
PO
Pete OlsonExecutive
CZ
Chao ZhangExecutive
TT
Tabbert TengExecutive
Board
JB
RJ
R. Jacob VogelsteinBoard director
ER
Evan RachlinBoard director
KV
WR
William RastetterBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$268.7M disclosed across 4 rounds · 2023–2026
▶$27.8MraisedApr 2026 · 7 investors · BiotechnologyRule 506(b)
▶$27.8MraisedApr 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shalini SharpDirector
- R. Jacob VogelsteinDirector
- Thomas MillerExecutive Officer, Director
- Fred ManbyExecutive Officer, Director
- Michael SecoraExecutive Officer
- Neil JosephsonExecutive Officer
- Mary TagliaferriDirector
- Kurt von EmsterDirector
- William RastetterDirector
- Jishnu BhattacharjeeDirector
- Evan RachlinDirector
- Pete OlsonExecutive Officer
- Offering amount
- $50M
- Amount sold
- $27.8M
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$99.3MraisedNov 2025 · 22 investors · BiotechnologyRule 506(b)
▶$99.3MraisedNov 2025 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jishnu BhattacharjeeDirector
- William RastetterDirector
- Fred ManbyExecutive Officer, Director
- Shalini SharpDirector
- Neil JosephsonExecutive Officer
- Michael SecoraExecutive Officer
- R. Jacob VogelsteinDirector
- Mary TagliaferriDirector
- Evan RachlinDirector
- Thomas MillerExecutive Officer, Director
- Pete OlsonExecutive Officer
- Kurt von EmsterDirector
- Offering amount
- $125M
- Amount sold
- $99.3M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$38.4MraisedJun 2024 · 11 investors · BiotechnologyRule 506(b)
▶$38.4MraisedJun 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas MillerExecutive Officer, Director
- Tabbert TengExecutive Officer
- William RastetterDirector
- Evan RachlinDirector
- Fred ManbyExecutive Officer, Director
- R. Jacob VogelsteinDirector
- Kurt von EmsterDirector
- Jishnu BhattacharjeeDirector
- Neil JosephsonExecutive Officer
- Offering amount
- $50M
- Amount sold
- $38.4M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$103.2MraisedOct 2023 · 18 investors · BiotechnologyRule 506(b)
▶$103.2MraisedOct 2023 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fred ManbyExecutive Officer, Director
- R. Jacob VogelsteinDirector
- Chao ZhangExecutive Officer
- Evan RachlinDirector
- Tabbert TengExecutive Officer
- Thomas MillerExecutive Officer, Director
- William RastetterDirector
- Kurt von EmsterDirector
- Jishnu BhattacharjeeDirector
- Offering amount
- $110M
- Amount sold
- $103.2M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Legal entities · 1
corporate structureIambic Therapeutics, Inc.Delaware
In the news
Frequently asked questions
- Who founded Iambic Therapeutics, Inc.?
- Iambic Therapeutics, Inc. was founded by Fred Manby, Thomas Miller in 2019.
- Who are Iambic Therapeutics, Inc.'s investors?
- Iambic Therapeutics, Inc.'s investors include Abingworth, Nexus Venture Partners, Nexus Ventures.
- How much funding has Iambic Therapeutics, Inc. raised?
- Iambic Therapeutics, Inc. has disclosed $268.7M raised across 4 rounds.
- Where is Iambic Therapeutics, Inc. headquartered?
- Iambic Therapeutics, Inc. is headquartered in San Diego, US.